2022—2023年柳州市B型流感病毒全基因组遗传特征分析  

Genetic characteristics analysis of the whole genome of influenza B virus in Liuzhou City from 2022 to 2023

作　　者：余钧池[1] 陈柳军[1] 刘一[1] 陈艺肖 陈然琼 居昱[2] YU Junchi;CHEN Liujun;LIU Yi;CHEN Yixiao;CHEN Ranqiong;JU Yu(Microbiological Laboratory,Liuzhou Center for Disease Control and Prevention,Liuzhou,Guangxi 545007,China;Acute Infectious Disease Prevention and Control Department,Guangxi Center for Disease Control and Prevention,Nanning,Guangxi 530000,China)

机构地区：[1]柳州市疾病预防控制中心微生物检验所,广西柳州545007 [2]广西壮族自治区疾病预防控制中心急性传染病防制所,广西南宁530000

出　　处：《职业与健康》2024年第21期2900-2908,共9页Occupation and Health

基　　金：广西重大传染病防控与生物安全应急响应重点实验室(广西壮族自治区疾病预防控制中心)开放基金(GKLKP-KF-202204)。

摘　　要：目的分析2022—2023年柳州市B型流感病毒全基因组遗传特征,了解柳州市B型流感病毒变异情况及与WHO推荐疫苗株的匹配性。方法利用DNAStar、MEGA等生物信息学软件对分离的31株B型流感病毒的全基因序列进行比对构建基因进化树,分析同源性及氨基酸位点变异。结果2022年柳州市B型流感病毒分离株属于C.1亚分支,只有神经氨酸酶(neuraminidase,NA)、膜蛋白(matrix protein,MP)和聚合酶A(polymerase A,PA)3个基因片段与2020—2022年北半球疫苗推荐株B/Washington/02/2019在同一进化分支。2023年B型流感病毒分离株属于C.5.6或C.5.7亚分支,8个基因片段均与2022—2024年北半球疫苗推荐株B/Austria/1359417/2021在同一进化分支;相对于B/Austria/1359417/2021,2022—2023年柳州市B型流感病毒分离株血凝素(hemagglutinin,HA)基因在抗原决定簇和受体结合位点发生的氨基酸变异具有流行病学意义。柳州市31株B型流感病毒分离株HA蛋白和NA蛋白均未出现糖基化插入或缺失,未发生NA蛋白酶催化活性位点及耐药位点突变。部分流感病毒在非结构蛋白(non-structural protein,NS)和核蛋白(nucleoprotein,NP)的关键位点上发生了氨基酸变异,而组成RNA聚合酶的PA、聚合酶B1(polymerase B1,PB1)及聚合酶B2(polymerase B2,PB2)的3个蛋白存在2种主要共同变异方式。结论2022年柳州市B型流感病毒与北半球疫苗推荐株B/Austria/1359417/2021的匹配性较差,2023年柳州市B型流感病毒与北半球疫苗推荐株B/Austria/1359417/2021的匹配性较好。流感病毒HA蛋白抗原决定簇和受体结合位点上氨基酸变异可能是引起B型流感病毒在柳州市流行的主要原因之一,流感病毒对使用的神经氨酸酶抑制剂的抗流感药物敏感。objective To analyze the genetic characteristics of the whole genome of the influenza B virus in Liuzhou City from 2022to 2023,understand the variation of influenza B virus in Liuzhou City and its compatibility with the vaccine strains recommended by WHO.Methods Bioinformatics software such as DNAStar and MEGA were used to compare the complete gene sequences of31 isolated influenza B virus,construct a gene evolutionary tree,and analyze homology and amino acid site variations.Results The influenza B virus isolated in Liuzhou City in 2022 belong to the C.1 sub-branch.Only the neuraminidase(NA),matrix protein(MP)and polymerase A(PA)gene fragments share the same evolutionary branch as the northern hemisphere vaccine recommended strain B/Washington/02/2019 from 2020 to 2022.The influenza B virus in 2023 belonged to the C.5.6 or C.5.7 sub-branch,and all eight gene fragments were in the same evolutionary branch as the B/Austria/1359417/2021 recommended for the 2022 to 2024vaccine.Relative to the vaccine recommended strain B/Austria/1359417/2021,the amino acid variation in the hemagglutinin(HA)gene of the influenza B virus isolated in Liuzhou City from 2022 to 2023 had epidemiological significance in the antigenic determinants and receptor binding sites.Respectively the Ha and Na proteins of 31 influenza B virus isolated from Liuzhou City did not show glycosylation insertion or deletion,and there were no mutations in the catalytic activity site and resistance site of Na protease.Some influenza viruses had amino acid mutations at key sites of the non-structural protein(NS)and nucleoprotein(NP),and the PA,polymerase B1(PB1)and polymerase B2(PB2),which composed RNA polymerase,had two main common variation patterns.Conclusion The influenza B virus isolates from Liuzhou City in 2022 was poorly matched to the northern hemisphere vaccine recommended strain B/Austria/1359417/2021,and the influenza B virus isolates from Liuzhou City in 2023 was well matched to the 2023 Northern Hemisphere vaccine recommended strain B/Austria/1359

关 键 词：B型流感病毒 全基因组 遗传特征 疫苗推荐株 

分 类 号：R117[医药卫生—公共卫生与预防医学]